This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

ISIS-4 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

ISIS-4 examined the role of the following interventions in the management of acute myocardial infarction:

  • one month of oral captopril
  • one month of oral isosorbide mononitrate
  • 24 hours of intravenous magnesium

Using captopril, there was a significant reduction in 5 week mortality versus placebo which appeared to be maintained in the long-term. There was an increase of:

  • 52 per 1000 in hypotension considered serious enough to require termination of study treatment
  • 5 per 1000 in reported cardiogenic shock
  • 5 per 1000 in some degree of renal failure

Using mononitrate, there was no significant reduction in 5 week mortality. There was an increase of 15 per 1000 in hypotension.

Using magnesium, there was no significant reduction in 5 week mortality.

Conclusions:

  • in an acute MI, early treatment with an ACE inhibitor, in patients without clear contraindications, prevents about 5 deaths per 1000 in the first month
  • benefits appear to persist for at least the first year
  • benefits appear to be be greatest in high-risk patients

Reference:

  • ISIS-4 (1995). ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected myocardial infarction. Lancet, 334,669-84.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.